Abstract
Final primary analysis in the original cohort of KGOG3046/TRU-D: A phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer (LBA 8)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have